ProMetic gains controlling stake in PRDT
This article was originally published in Clinica
Biopharmaceutical firm ProMetic Life Sciences has secured a majority stake in Pathogen Removal and Diagnostic Technologies (PRDT) from US emergency response organisation American Red Cross. The non-cash transaction sees ProMetic increase its stake from 26% to 77% in exchange for a tapering royalty on PRDT revenue that will be paid to American Red Cross over an unspecified period of time. The remaining 23% of common stock in PRDT will continue to be held by its academic co-founders. American Red Cross will maintain a position on PRDT’s board of directors. This deal gives ProMetic access to PRDT’s prion capture materials used for blood cell filtration, which are shown to significantly reduce the risk of transmission of variant Creutzfeldt-Jakob disease (vCJD) from blood-derived products.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals